TOP STORY
Brightly colored prescription warning labels applied by pharmacies fail to adequately capture the attention of older patients, suggesting that current labeling standards should be reconsidered to make them more effective, according to a study published online June 14 in PLoS ONE. » More |
CONTINUING EDUCATION
Late-life depression can occur in up to 50% of patients. Pharmacists can screen for unidentified cases and advocate for routine measurement of symptom severity.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login. |
EDITOR’S PICK
New contraindications and modified cardiovascular parameters for fingolimod
On May 15, FDA announced completion of their safety review of fingolimod (Gilenya, Novartis), an oral agent approved in September for the treatment of relapsing forms of multiple sclerosis. The safety review was initiated after a report of a patient who died within 24 hours of taking the first dose of fingolimod. » Click here. |
CLINICAL NEWS
Vitamin D plus calcium supplementation consistently reduced mortality among elderly patients compared with vitamin D supplementation alone, according to a study published online May 17 in the Journal of Clinical Endocrinology and Metabolism. » More |
|
Patients treated with olmesartan may be at risk of a severe form of spruelike enteropathy, which improves when the drug is discontinued, according to a case series study published online June 25 in Mayo Clinic Proceedings. » More |
|
Older women with acute pyelonephritis can be successfully and safely treated with oral ciprofloxacin for 7 days, according to a study published online June 21 in The Lancet. » More |
FDA NEWS
FDA recently released the results of an analysis of a limited number of samples of hydroxyprogesterone caproate active pharmaceutical ingredients and compounded hydroxyprogesterone caproate, finding no major safety concerns. » More |
Survey
a) "Lock-in" programs – limiting access for high utilizers to single pharmacy and/or physician provider
b) Tighter dispensing limits on the number of units and/or prescriptions a patient can receive for controlled meds
c) Limiting coverage to only long-acting formulations with effective abuse-deterrant delivery systems
d) More broad and advanced state-based controlled prescription monitoring/surveillance systems
e) Limiting coverage of long-acting opioid prescriptions to select specialty providers
f) Other
Click here and see what your colleagues think, too.
Want to see the results of our last survey about specialty pharmacy services? Click here. |
|
Digital Edition |
|
|
